ATRA vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ATRA vs JNJ: Head-to-Head Comparison
This page compares Atara Biotherapeutics, Inc. (ATRA) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.